Want to see HK:1643 full AI Analyst Report?
Top Page
Modern Chinese Medicine Group Co. Ltd.
(1643)
Select Model
Select Model
Rating:48Neutral
Price Target:
HK$0.89
â–²(74.71% Upside)
Action:Reiterated
Date:07/14/26
The score is held back primarily by deteriorating fundamentals (revenue decline, margin compression, and a move to losses) and weak recent cash-flow quality, despite a strong low-leverage balance sheet that reduces solvency risk. Technicals further weigh on the score due to a pronounced downtrend with bearish momentum, while valuation is constrained by a loss-driven negative P/E and no provided dividend yield.
Positive Factors
Low Leverage
Minimal debt reduces solvency risk and interest burden, giving the company financial flexibility to withstand weak demand and fund operational recovery without relying heavily on external financing.
Negative Factors
Persistent Revenue Decline
A multi-year revenue contraction signals weakening demand, distribution, or product competitiveness. If sustained, lower scale can limit investment capacity and create continuing pressure on profitability and market position.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Minimal debt reduces solvency risk and interest burden, giving the company financial flexibility to withstand weak demand and fund operational recovery without relying heavily on external financing.
Read all positive factors
Modern Chinese Medicine Group Co. Ltd. (1643) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$597.60M
Dividend Yield2.98%
Average Volume (3M)165.60K
Price to Earnings (P/E)―
Beta (1Y)0.49
Revenue Growth2.06%
EPS Growth-298.25%
CountryHK
Employees189
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)-0.02
Shares Outstanding720,000,000
10 Day Avg. Volume163,200
30 Day Avg. Volume165,600
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.61
Price to Sales (P/S)2.14
P/FCF Ratio-18.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Modern Chinese Medicine Group Co. Ltd. Business Overview & Revenue Model
Company Description
As an investment holding company, Modern Chinese Medicine Group Co., Ltd. manufactures and distributes traditional Chinese pharmaceutical products, primarily targeting the middle-aged and elderly populations across the People's Republic of China. ...
How the Company Makes Money
The company makes money primarily by selling its traditional Chinese medicine products to customers through commercial distribution channels. Revenue is generated when the group manufactures (or arranges the manufacture of) TCM products and recogn...
Modern Chinese Medicine Group Co. Ltd. Financial Statement Overview
Summary
Income Statement
33
Negative
Balance Sheet
86
Very Positive
Cash Flow
40
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 141.42M | 214.07M | 344.07M | 399.66M | 360.69M |
| Gross Profit | 22.73M | 55.20M | 104.17M | 170.79M | 158.43M |
| EBITDA | -4.63M | 29.82M | 74.75M | 130.03M | 117.02M |
| Net Income | -13.21M | 9.67M | 48.80M | 87.83M | 81.78M |
Balance Sheet | |||||
| Total Assets | 543.63M | 540.31M | 528.53M | 501.53M | 395.94M |
| Cash, Cash Equivalents and Short-Term Investments | 229.81M | 229.67M | 286.27M | 282.26M | 176.09M |
| Total Debt | 69.03K | 135.00K | 72.00K | 393.00K | 410.00K |
| Total Liabilities | 45.43M | 56.08M | 55.64M | 78.60M | 58.58M |
| Stockholders Equity | 498.20M | 484.23M | 472.89M | 422.93M | 337.36M |
Cash Flow | |||||
| Free Cash Flow | -16.58M | -55.32M | 3.38M | 114.06M | -12.87M |
| Operating Cash Flow | 4.85M | 58.98M | 8.48M | 125.79M | 57.60M |
| Investing Cash Flow | -35.37M | -115.49M | -4.19M | -11.05M | -70.05M |
| Financing Cash Flow | 28.68M | -144.00K | -326.00K | -8.73M | 115.76M |
Modern Chinese Medicine Group Co. Ltd. Technical Analysis
Positive
0.51
Price Trends
0.88
Negative
1.60
Negative
1.34
Negative
Market Momentum
-0.04
Negative
47.31
Neutral
62.61
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1643, the sentiment is Positive. The current price of 0.51 is below the 20-day moving average (MA) of 0.81, below the 50-day MA of 0.88, and below the 200-day MA of 1.34, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 47.31 is Neutral, neither overbought nor oversold. The STOCH value of 62.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1643.
Modern Chinese Medicine Group Co. Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | HK$779.10M | 7.75 | 13.59% | 7.40% | 10.63% | 39.44% | |
65 Neutral | HK$703.66M | 4.73 | 7.52% | 3.67% | 7.05% | 22.46% | |
64 Neutral | HK$4.03B | 11.61 | 4.14% | 6.49% | -13.93% | -25.30% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$345.46M | 86.11 | 0.34% | 84.69% | -8.30% | -44.44% | |
48 Neutral | HK$597.60M | -11.77 | -8.62% | 2.98% | 2.06% | -298.25% | |
43 Neutral | HK$139.08M | -4.57 | -21.66% | 0.48% | -6.71% | 43.14% |
* Healthcare Sector Average
HK:1643
Modern Chinese Medicine Group Co. Ltd.
0.83
0.12
16.90%
HK:1666
Tong Ren Tang Technologies Co
3.19
-1.48
-31.71%
HK:0897
Wai Yuen Tong Medicine Holdings Limited
0.31
-0.07
-18.42%
HK:0950
Lee's Pharmaceutical Holdings Limited
1.23
-0.73
-37.31%
HK:1498
PuraPharm Corp. Ltd.
0.26
-0.18
-40.91%
HK:0239
Pak Fah Yeow International Limited
2.48
0.17
7.27%
Modern Chinese Medicine Group Co. Ltd. Corporate Events
Modern Chinese Medicine Group Sets August Board Meeting for Interim Results and Dividend Review
Aug 13, 2026
Modern Chinese Medicine Group Co., Ltd. has scheduled a board meeting for 28 August 2026 to review and approve the interim financial results for the six months ended 30 June 2026. The board will also consider proposing an interim dividend, a decis...
Modern Chinese Medicine Wins Unanimous Backing for AGM Mandates and Governance Changes
May 29, 2026
Modern Chinese Medicine Group Co. Ltd. reported that all resolutions at its 29 May 2026 annual general meeting were approved by shareholders via poll, with 412,479,000 votes cast entirely in favour on each item. The meeting endorsed the 2025 audit...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.